← All organizations
Highest phase reached
Phase 2
First clinical trial
Apr 1, 2003First marketed drug
Jun 25, 1943First NDA
Mar 9, 1960Last known activity
Apr 1, 2003
Acquired by Schering-Plough → Merck on Jan 1, 1971
Timeline
1850s
- Jun 1, 1851
Schering— Founded
1950s
- Jan 1, 1957
White Laboratories— Acquired
- Apr 5, 1957
anisindione— NDA Secondary Org
1970s
- Jan 1, 1971
Schering-Plough— Acquired By
- Aug 3, 1979
methyltestosterone— Marketing Organization
1980s
- Dec 27, 1985
quazepam— NDA Organization
2000s
- Jan 1, 2009
Merck— Now
Drugs by trial phase (1 distinct, 1 trials)
Phase 2 (1 own, 0 via acquisition)
Indications
Approved for
- Acute Coronary Syndrome
- Angina Pectoris
- Asthma
- Atrial Fibrillation
- Atrial Flutter
- Bradycardia
- Collagen Diseases
- Gastrointestinal Diseases
- Hyperhidrosis
- Hyperinsulinism
- Hypertension
- Inflammation
- Insulinoma
- Multiple Sclerosis
- Peptic Ulcer
- Pneumonia
- Prostatic Neoplasms
- Psychotic Disorders
- Pulmonary Disease, Chronic Obstructive
- Respiration Disorders
- Rheumatic Diseases
- Rhinitis, Allergic, Seasonal
- Short Bowel Syndrome
- Skin Diseases
- Sleep Initiation and Maintenance Disorders
- Tachycardia, Ventricular
Marketed drugs (48)
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (1)
- NCT00162851CollaboratorPhase 2Apr 1, 2003
Details
- Founded
- Berlin, DE Jun 1, 1851
- First NDA
- Mar 9, 1960
- Last known activity
- Apr 1, 2003
Designations held
- Orphan drug
- Priority review